FORMA THERAPEUTICS ANNOUNCES PRESENTATION AT THE 2018 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

FT-2102 IDH1m Inhibitor Clinical Data Selected for Oral Presentation

WATERTOWN, Mass. – May 10, 2018 – FORMA Therapeutics (FORMA), a fully-integrated research and development biotechnology company, announced today an abstract featuring the company’s selective, small molecule IDH1m inhibitor, FT-2102, has been selected for an oral presentation at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from June 1-5, 2018 in Chicago, Illinois. Details on the presentation are included below.

Date and Time: Monday, June 4, 2018, 4:30 PM – 6:00 PM

Session Title: Targeted Therapy in Leukemia

Session Type: Oral Abstract Session

Title: A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Abstract No.: 7009

About FORMA

FORMA Therapeutics’ scientists are passionate about discovering and developing medicines that will make a difference in oncology, inflammation & immunity, neurodegeneration, and other serious diseases. The Company’s fully integrated R&D team drives discovery and early clinical development of therapeutics for qualified targets in the areas of epigenetics, protein homeostasis, and metabolism. Leveraging a world class network of academic investigators, clinical experts and partners, FORMA combines deep biology insight, chemistry expertise and early clinical development capabilities, to create drug candidates providing profound patient benefit.

FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with operations in Watertown, MA and Branford, CT. www.formatherapeutics.com

Join our conversation on Twitter @FORMAInc.

Media Contact

For FORMA Therapeutics
Kari Watson or Kara Mazey, +1 781-235-3060
kwatson@macbiocom.com or kmazey@macbiocom.com
MacDougall Biomedical Communications